Cargando…

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer’s Disease Therapeutic Antibodies

Alzheimer’s disease (AD) is a specific neurodegenerative disease. This study adopts single-chain variable fragments (scFvs) as a potential immunotherapeutic precursor for AD. According to the remarkable effects of monoclonal antibodies, such as the depolymerization or promotion of Aβ42 efflux by Cre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Xing, Xu, Lipeng, Zhang, Jianhao, Wang, Yidan, Wu, Zirui, Sun, Wenjing, Yao, Xin, Wang, Xu, Guan, Shanshan, Shan, Yaming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179127/ https://www.ncbi.nlm.nih.gov/pubmed/37176076 http://dx.doi.org/10.3390/ijms24098371

Ejemplares similares

Amyloid Fragmentation and Disaggregation in Yeast and Animals
por: Kushnirov, Vitaly V., et al.
Publicado: (2021)

Molecular mechanisms of amyloid disaggregation
por: Low, Kimberly Jia Yi, et al.
Publicado: (2021)

Single Chain Variable Fragment Against Aβ Expressed in Baculovirus Inhibits Abeta Fibril Elongation and Promotes its Disaggregation
por: Zhang, Ying, et al.
Publicado: (2015)

Tryptophan-galactosylamine conjugates inhibit and disaggregate amyloid fibrils of Aβ42 and hIAPP peptides while reducing their toxicity
por: Paul, Ashim, et al.
Publicado: (2020)

Release of frustration drives corneal amyloid disaggregation by brain chaperone
por: Low, Jia Yi Kimberly, et al.
Publicado: (2023)

Polyphenolic Biflavonoids Inhibit Amyloid-Beta Fibrillation and Disaggregate Preformed Amyloid-Beta Fibrils
por: Choi, Erika Y., et al.
Publicado: (2020)

Biflavonoid-Induced Disruption of Hydrogen Bonds Leads to Amyloid-β Disaggregation
por: Windsor, Peter K., et al.
Publicado: (2021)

The Ability of Some Polysaccharides to Disaggregate Lysozyme Amyloid Fibrils and Renature the Protein
por: Makshakova, Olga, et al.
Publicado: (2023)

Dual Inhibitors of Amyloid-β and Tau Aggregation with Amyloid-β Disaggregating Properties: Extended In Cellulo, In Silico, and Kinetic Studies of Multifunctional Anti-Alzheimer’s Agents
por: Pasieka, Anna, et al.
Publicado: (2021)

Activation Energy of Aggregation-Disaggregation Self-Oscillation of Polymer Chain
por: Hara, Yusuke, et al.
Publicado: (2012)

γ-AApeptides–based Small Molecule Ligands That Disaggregate Human Islet Amyloid Polypeptide
por: Bolarinwa, Olapeju, et al.
Publicado: (2020)

Chitosan Oligosaccharides Inhibit/Disaggregate Fibrils and Attenuate Amyloid β-Mediated Neurotoxicity
por: Dai, Xueling, et al.
Publicado: (2015)

Evaluation of Amyloid Polypeptide Aggregation Inhibition and Disaggregation Activity of A-Type Procyanidins
por: Tanaka, Taisei, et al.
Publicado: (2021)

Hsp70 targets Hsp100 chaperones to substrates for protein disaggregation and prion fragmentation
por: Winkler, Juliane, et al.
Publicado: (2012)

Inhibition Mechanisms of (−)-Epigallocatechin-3-gallate and Genistein on Amyloid-beta 42 Peptide of Alzheimer’s Disease via Molecular Simulations
por: Fang, Mei, et al.
Publicado: (2022)

Design, Synthesis of N-phenethyl Cinnamide Derivatives and Their Biological Activities for the Treatment of Alzheimer’s Disease: Antioxidant, Beta-amyloid Disaggregating and Rescue Effects on Memory Loss
por: Chai, Tian, et al.
Publicado: (2018)

The effect of α-tocopherol, α- and γ-tocotrienols on amyloid-β aggregation and disaggregation in vitro
por: Ibrahim, Nor Faeizah, et al.
Publicado: (2021)

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia
por: Bibl, Mirko, et al.
Publicado: (2012)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Amyloid-β 1–24 C-terminal truncated fragment promotes amyloid-β 1–42 aggregate formation in the healthy brain
por: Mazzitelli, Sonia, et al.
Publicado: (2016)

Small Bifunctional Chelators That Do Not Disaggregate Amyloid β Fibrils Exhibit Reduced Cellular Toxicity
por: Sharma, Anuj K., et al.
Publicado: (2014)

Disaggregation of Islet Amyloid Polypeptide Fibrils as a Potential Anti-Fibrillation Mechanism of Tetrapeptide TNGQ
por: Abioye, Raliat O., et al.
Publicado: (2022)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

In Vivo Detection of Amyloid-β Deposits Using Heavy Chain Antibody Fragments in a Transgenic Mouse Model for Alzheimer's Disease
por: Nabuurs, Rob J. A., et al.
Publicado: (2012)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Oligomer Formation by Amyloid-β42 in a Membrane-Mimicking Environment in Alzheimer’s Disease
por: Rosenberry, Terrone L., et al.
Publicado: (2022)

Patients with Alzheimer’s disease have an increased removal rate of soluble beta-amyloid-42
por: Zaretsky, Dmitry V., et al.
Publicado: (2022)

High Soluble Amyloid-β(42) Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer’s Disease-Causing Mutations
por: Sturchio, Andrea, et al.
Publicado: (2022)

Cellular Prion Protein as a Receptor of Toxic Amyloid-β42 Oligomers Is Important for Alzheimer’s Disease
por: Zhang, Yuan, et al.
Publicado: (2019)

Potential Alzheimer's disease therapeutic nano-platform: Discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles
por: Kim, Jaehoon, et al.
Publicado: (2023)

Comparison of the amyloid pore forming properties of rat and human Alzheimer’s beta-amyloid peptide 1-42: Calcium imaging data
por: Di Scala, Coralie, et al.
Publicado: (2016)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Neural Fourier Energy Disaggregation
por: Nalmpantis, Christoforos, et al.
Publicado: (2022)

Formation of the 42-mer Amyloid β Radical and the Therapeutic Role of Superoxide Dismutase in Alzheimer's Disease
por: Murakami, Kazuma, et al.
Publicado: (2011)

Aβ(1–42) Fibril Structure Illuminates Self-recognition and Replication of Amyloid in Alzheimer’s
por: Xiao, Yiling, et al.
Publicado: (2015)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

Noncanonical regulation of imprinted gene Igf2 by amyloid-beta 1–42 in Alzheimer’s disease
por: Fertan, Emre, et al.
Publicado: (2023)

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity
por: Izzo, Nicholas J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_97rl5ua0482p9oh90qh85fp8iu